<DOC>
	<DOCNO>NCT01277796</DOCNO>
	<brief_summary>Current standard therapy chemotherapy ( CT ) Cutaneous Leishmaniasis ( CL ) expensive , toxic/allergenic , frequently ineffective , burdensome , often unavailable . Thermotherapy clinically validate first line alternative treatment Cutaneous Leishmaniasis South America . However , current heat-delivery modality either costly lack governmental approval require make widely available endemic area . The investigator adapt reliable , safe , low-cost heat pack Cutaneous Leishmaniasis investigator name HECT-CL device . In pilot study investigator enroll 25 patient either fail candidate pentivalent antimony . The hypothesis state HECT-CL device demonstrate efficacy non-statistically inferior estimate current South American Pentavalent Antimonial cure rate ( 76 % ) demonstrate basic safety tolerability .</brief_summary>
	<brief_title>Pilot Study Using Heat Pack Treat Cutaneous Leishmaniasis</brief_title>
	<detailed_description />
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis , Cutaneous</mesh_term>
	<criteria>CL diagnose skin smear ( WHO method ) , biopsy , culture , PCR age 880 year old 3 lesion ulcerative nonulcerative ulcer less 4 cm diameter . allergy , prohibitive side effect standard chemotherapy , contraindication antimonial treatment ( e.g . cardiac arrhythmia ) capable signing inform consent capable guardian ( case minor ) . Children â‰¥ 8 year age must give write verbal informed assent along write consent guardian . lesion less 2cm nose , mouth , ear , eye . clinically diagnosed mucosal involvement . evidence lymph node involvement exam . unable unwilling commit treatment followup plan . prior CL treatment within last 1 month . pregnant lactating uncontrolled severe systemic illness immunocompromised state .</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>